1. Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.
- Author
-
He Y, Barker SJ, MacDonald AJ, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock DT, Jiang S, Libri NA, Semper AE, Rosenberg WM, and Lustigman S
- Subjects
- Animals, Antigen Presentation immunology, Cytokines biosynthesis, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Membrane Glycoproteins immunology, Mice, Spike Glycoprotein, Coronavirus, Th2 Cells immunology, Toll-Like Receptor 2 immunology, Toll-Like Receptor 4 immunology, Viral Envelope Proteins immunology, Adjuvants, Immunologic, Antigen-Presenting Cells immunology, Antigens, Helminth immunology, Helminth Proteins immunology, Lymphocyte Activation immunology, Recombinant Proteins immunology, Th1 Cells immunology
- Abstract
We previously reported that rOv-ASP-1, a recombinant Onchocerca volvulus activation associated protein-1, was a potent adjuvant for recombinant protein or synthetic peptide-based Ags. In this study, we further evaluated the adjuvanticity of rOv-ASP-1 and explored its mechanism of action. Consistently, recombinant full-length spike protein of SARS-CoV or its receptor-binding domain in the presence of rOv-ASP-1 could effectively induce a mixed but Th1-skewed immune response in immunized mice. It appears that rOv-ASP-1 primarily bound to the APCs among human PBMCs and triggered Th1-biased proinflammatory cytokine production probably via the activation of monocyte-derived dendritic cells and the TLR, TLR2, and TLR4, thus suggesting that rOv-ASP-1 is a novel potent innate adjuvant.
- Published
- 2009
- Full Text
- View/download PDF